SHISA8 | Shisa family member 8 | Predicted membrane proteins
| | | | | Tissue enhanced |
SLC10A4 | Solute carrier family 10, member 4 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC16A9 | Solute carrier family 16, member 9 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC18A2 | Solute carrier family 18 (vesicular monoamine transporter), member 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC27A6 | Solute carrier family 27 (fatty acid transporter), member 6 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC35D3 | Solute carrier family 35, member D3 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC47A1 | Solute carrier family 47 (multidrug and toxin extrusion), member 1 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLITRK4 | SLIT and NTRK-like family, member 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
SNCG | Synuclein, gamma (breast cancer-specific protein 1) | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
SPINK13 | Serine peptidase inhibitor, Kazal type 13 (putative) | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SSTR5 | Somatostatin receptor 5 | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ST8SIA5 | ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
STK32A | Serine/threonine kinase 32A | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
SULT2A1 | Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
SV2C | Synaptic vesicle glycoprotein 2C | Predicted membrane proteins
| | | | | Tissue enhanced |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TBX3 | T-box 3 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
TLX2 | T-cell leukemia homeobox 2 | Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
TMEM63C | Transmembrane protein 63C | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
TMIE | Transmembrane inner ear | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
TPD52L1 | Tumor protein D52-like 1 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
UNC80 | Unc-80 homolog (C. elegans) | Predicted intracellular proteins
| | | | | Tissue enhanced |
UTS2 | Urotensin 2 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
VAT1L | Vesicle amine transport 1-like | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
VEPH1 | Ventricular zone expressed PH domain-containing 1 | Predicted intracellular proteins
| | | | | Tissue enhanced |
VSTM2A | V-set and transmembrane domain containing 2A | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
VSX1 | Visual system homeobox 1 | Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
WNT8B | Wingless-type MMTV integration site family, member 8B | Predicted secreted proteins
| | | | | Tissue enhanced |
ZBED6CL | ZBED6 C-terminal like | Predicted intracellular proteins
| | | | | Tissue enhanced |